文献速递白血病淋巴瘤

毛细胞白血病2026年诊断、风险分层与治疗更新

Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.
PubMed 文献 · Am J Hematol · 2026-09-15

该综述更新了毛细胞白血病(HCL)及HCL样疾病的诊断、风险分层与治疗。诊断依赖形态学、流式免疫表型、骨髓活检及BRAFV600E突变。仅症状性患者需治疗,一线用嘌呤类似物,复发/难治用BRAF抑制剂联合利妥昔单抗等靶向药物。

要点

  • 诊断需形态学、流式(CD11c/CD103/CD123/CD25)、骨髓活检及BRAFV600E突变。
  • 风险分层依据脾大、白细胞增多、外周血毛细胞数及IGHV突变状态。
  • 仅症状性HCL治疗,一线嘌呤类似物,复发/难治用BRAFi联合R等靶向治疗。

核心结论

  • HCL及HCL样疾病异质性强,诊断需综合形态学、免疫表型、骨髓活检和BRAFV600E突变。
  • 仅症状性患者需治疗,一线嘌呤类似物,复发/难治可用BRAF抑制剂联合利妥昔单抗等靶向药物。

主要发现

  • HCL诊断基于毛细胞形态学证据、特征性流式免疫表型(CD11c、CD103、CD123、CD25)、骨髓活检(明确浸润程度及Annexin A1免疫组化)和BRAFV600E突变。
  • 风险分层基于脾大、白细胞增多、外周血毛细胞数及IGHV突变状态;VH4-34阳性、TP53突变及HCL-V预后差。
  • 仅症状性HCL患者需治疗;一线用嘌呤类似物,克拉屈滨联合利妥昔单抗的化学免疫治疗日益常用。
  • 复发/难治基于BRAF抑制剂联合利妥昔单抗、MEK抑制剂、BTK抑制剂和/或Bcl-2抑制剂。

关键数值与推荐

  • 诊断需形态学毛细胞、流式CD11c/CD103/CD123/CD25、骨髓活检Annexin A1及BRAFV600E突变。
  • 风险分层指标包括脾大、白细胞增多、外周血毛细胞数及IGHV突变状态。
  • 仅症状性患者治疗;一线嘌呤类似物,可用克拉屈滨联合利妥昔单抗。
  • 复发/难治用BRAF抑制剂联合利妥昔单抗、MEK抑制剂、BTK抑制剂和/或Bcl-2抑制剂。

临床怎么用

  • 疑似HCL应完善形态学、流式免疫表型、骨髓活检及BRAFV600E突变检测以确诊。
  • 无症状患者观察,症状性患者一线选择嘌呤类似物或克拉屈滨联合利妥昔单抗。
  • 复发/难治患者可选用BRAF抑制剂联合利妥昔单抗、MEK抑制剂、BTK抑制剂或Bcl-2抑制剂。

局限性

  • 不同治疗的最佳顺序尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B-cell disorders characterized by the identification of hairy cells, a specific immunophenotypic and genetic profile, a different clinical course and the need for appropriate treatment. DIAGNOSIS: Diagnosis of HCL is based on morphological evidence of hairy cells, characteristic flow cytometric immunophenotype (CD11c, CD103, CD123, CD25) bone marrow trephine biopsy which makes it possible to specify the degree of tumoral bone marrow infiltration and presence of the Annexin A1 marker in immunohistochemistry, and presence of the BRAFV600E mutation. RISK STRATIFICATION: Progression of patients with HCL is based on a large splenomegaly, leukocytosis, a high number of hairy cells in the peripheral blood and the unmutated ImmunoGlobulin HeaVy (IGHV) chain variable region gene mutational status. VH4-34 positive HCL cases are associated with a poor prognosis, as well as the rare cases of HCL with TP53 mutations and HCL-V. TREATMENT: Patients should be treated only if HCL is symptomatic. Chemotherapy with purine analogs (PNAs) are indicated in first-line HCL patients. The use of chemo-immunotherapy combining cladribine (CDA) and rituximab (R) represents an increasingly used therapeutic approach. Management of relapsed/refractory disease is based on the use of BRAF inhibitors (BRAFi) plus R, MEK inhibitors (MEKi), Bruton Tyrosine Kinase inhibitors (BTKi) and/or Bcl-2 inhibitors (Bcl-2i). The optimal sequence of the different treatments remains to be determined.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Troussard X, Maître E, Paillassa J, et al. Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment. Am J Hematol. 2026. PMID: 42740575. doi:10.1002/ajh.70441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。